FGD4 and Familial prostate cancer: If used in treatment of prostate cancer, inhibition of FGD4 would be limited to short-term, localized therapy, compared to the sustained inactivation of FGD4 in Schwann cells of patients with CMT Type 4H, and is unlikely to have the same effects.